References
- . Bays HE. Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert Rev Cardiovasc Ther. 2004;2(4):485–501
- . Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev Cardiol. 2003;6(4):179–188
- . Bays HE, Rader DJ. Does nicotinic acid (niacin) lower blood pressure? Int J Clin Pract. 2009;63(1):151–159
- . Kastelein JJ, Akdim F, Stroes ES,. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431–1443
- . Barter PJ, Caulfield M, Eriksson M,. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007:22;357(21):2109–2122
- . Harrison DG, Brown WV, Raggi P. Enhanced hype. Am J Cardiol. 2008;102(3):368–369
- . Stein EA. After ENHANCE: is more LDL cholesterol lowering even better? Clin Chem. 2008;54(6):940–942
- . Fleg JL, Mete M, Howard BV,. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008;52(25):2198–2205
- . Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther. 2008;6(4):447–470